Investigation · July 2026
A documented account — with sources — of how a pandemic was constructed, managed, and sold
Between 2014 and 2019, a network of researchers was conducting what is called gain-of-function research — deliberately enhancing the transmissibility and virulence of bat coronaviruses. The key players:
In January 2018, Daszak, Baric, Shi Zhengli, and Dr. Vincent Munster (NIH/Rocky Mountain Laboratories, trained at Erasmus MC Rotterdam) co-authored a research proposal called DEFUSE, submitted to DARPA — the US military research agency. DEFUSE proposed inserting furin cleavage sites into bat coronaviruses to enhance human infectivity.
DARPA rejected the proposal. Their internal review noted it was too dangerous and lacked adequate biosafety provisions.
Months after the DARPA rejection, the same network published a peer-reviewed paper in Viruses (December 2018) studying WIV1-CoV — a SARS-like coronavirus directly isolated from bats at the Wuhan Institute of Virology. The authors: Munster (NIH/Rocky Mountain Laboratories), Baric (UNC), and Menachery (UNC) — the first author on the 2015 chimeric coronavirus paper demonstrating how to construct a SARS-like virus with pandemic potential. The paper's own conclusion: "bat-to-bat transmission is possible" for this WIV-origin virus. The same three names. The same virus family. Thirteen months before the outbreak began in Wuhan.
There is a related anomaly in the species data that has never been satisfactorily explained. Of all mammalian species tested, only five transmit SARS-CoV-2 efficiently: Egyptian fruit bats, Syrian golden hamsters, American mink, American deer mice, and North American white-tailed deer. Despite intensive surveillance efforts across Asia, no Chinese animal species has ever been identified as a natural reservoir. All five susceptible species are maintained as laboratory animals at Munster's Rocky Mountain Laboratories in Montana — the same facility that co-authored the 2018 Egyptian fruit bat paper. None are native to China.
The furin cleavage site itself carries an additional engineering marker. The 12-nucleotide insertion responsible for the PRRAR cleavage sequence — absent in all known closely related bat coronaviruses — is bracketed by a BsaXI Type IIS restriction enzyme recognition site. Type IIS enzymes cut DNA at a defined distance from their recognition sequence and are standard tools in synthetic biology for precise, seamless insertions. The BsaXI bracketing is independently verifiable against the published SARS-CoV-2 reference genome (NC_045512.2) and is consistent with the restriction-site engineering methodology described in Baric's own laboratory protocols.
In September 2021, a leaked internal DARPA assessment written by Major Joseph Murphy — a Marine Corps officer assigned to DARPA who reviewed the DEFUSE proposal — was published by DRASTIC and The Intercept. Murphy's conclusion was direct: "SARS-CoV-2 is an American-created recombinant bat vaccine, or its precursor virus." His memo further noted that the proposed research had proceeded without adequate biosafety provisions and that the absence of a furin cleavage site in naturally occurring bat coronaviruses, combined with its presence in SARS-CoV-2, was inconsistent with natural emergence. Murphy identified the NIAID CREID program (Centers for Research in Emerging Infectious Diseases) as the likely continuation funding mechanism after DARPA's rejection.
Here is a question almost no journalist asked: on what legal basis was a global pandemic declared when there were only a few thousand cases, mostly in one city in China?
The answer requires going back to 2009.
That year, WHO handled the H1N1 "swine flu" outbreak. To declare it a pandemic, they needed to meet certain criteria. In May 2009 — just weeks before the declaration — the WHO's pandemic preparedness webpage was quietly changed. The previous description of an influenza pandemic included the phrase "enormous numbers of deaths and illness." That phrase was removed. The new description read simply: "a new influenza virus appears against which the human population has no immunity."
No severity. No death toll threshold. No minimum number of cases.
Dr. Wolfgang Wodarg, a German epidemiologist and member of the Council of Europe, called it in December 2009 for what it was: the criteria had been lowered to make a pandemic declarable without the disease needing to actually be catastrophic. The Council of Europe launched a formal inquiry. The pharmaceutical industry had already sold billions in stockpiled vaccines by then.
The definition stayed changed.
On January 22–23, 2020, WHO's Emergency Committee met to decide whether to declare a Public Health Emergency of International Concern (PHEIC) — the formal step before a pandemic. The case count in China: 309 confirmed cases, 6 deaths. Globally: 5 cases in 4 countries.
The committee could not reach consensus. It was split. No PHEIC was declared.
Between January 23 and 30, WHO Director-General Tedros Adhanom Ghebreyesus traveled to Beijing and met with President Xi Jinping.
On January 30, 2020, the Emergency Committee reconvened. Now: 7,736 cases in China (0.00055% of the Chinese population), 107 outside China. This time, a PHEIC was declared.
The pandemic itself was formally announced on March 11, 2020 — 118,000 cases across 114 countries, 4,291 deaths. At that point, the legal machinery that countries had built around WHO declarations began activating.
On February 1, 2020, a private teleconference was organized by Sir Jeremy Farrar (Wellcome Trust, later WHO Chief Scientist). Attendees included Dr. Anthony Fauci (NIAID), Dr. Francis Collins (NIH Director), Dr. Ron Fouchier (Erasmus MC Rotterdam), and Dr. Marion Koopmans (Erasmus MC Rotterdam). The topic: the genomic features of SARS-CoV-2 that looked engineered.
Within hours of that call, several participants who had expressed concern about a lab origin shifted their position. Six weeks later, on March 17, 2020, the paper "The Proximal Origin of SARS-CoV-2" appeared in Nature Medicine (Anderson, Garry, Holmes, Lipkin, Rambaut). It declared a natural origin "most plausible" and called lab-origin theories inconsistent with the data.
Emails released under FOIA showed that at least one co-author had privately estimated a 60–70% chance of lab origin before writing the opposite in the paper.
On February 19, 2020, The Lancet published a letter signed by 27 scientists, organized by Peter Daszak, "strongly condemning conspiracy theories" about a lab origin — without disclosing that Daszak himself ran the organization that funded the WIV research.
Both Fouchier and Koopmans — who attended the February 1 call — later served on the WHO COVID-19 Origins Investigation team in 2021, which concluded a lab origin was "extremely unlikely."
With the pandemic declared and emergency laws activated, governments rolled out a package of interventions. Most of them lacked robust scientific support at the time. Some have since been formally disproven.
In 2023, the Cochrane Collaboration — the gold standard of systematic medical reviews — published its updated analysis of 78 randomized controlled trials on physical interventions against respiratory viruses. The finding: "The pooled results of RCTs did not show a clear reduction in respiratory viral infection with the use of medical/surgical masks." The N95 data was similarly inconclusive.
This is not a fringe finding. This is the largest and most methodologically rigorous review of mask evidence in history. Governments mandated masks for two years without this level of evidence behind them. Mask procurement became a global industry worth tens of billions of dollars.
The 1.5-meter (or 6-foot) social distancing rule was based on a 1934 model by Wells that described large respiratory droplets falling to the ground within a certain distance. The model did not account for aerosol transmission — fine particles that can travel far beyond 1.5 meters and linger in indoor air for hours. The WHO itself acknowledged in mid-2020 (after initially denying it) that aerosol transmission was a major route of spread. The 1.5-meter rule was never updated to reflect this.
On February 16, 2021, the Hague District Court (Voorzieningenrechter) ruled the Dutch curfew unconstitutional. The court found that the government had failed to demonstrate the "special urgency" required by law, noting that curfew discussions had been ongoing for weeks before the decision — undermining the claim of emergency necessity. The government appealed, the court of appeal reversed the ruling, and parliament then passed emergency legislation to keep the curfew in place regardless.
The original judicial finding stands as a legal record: the curfew, as it was introduced, had no lawful basis.
When COVID-19 hit, one antiviral was fast-tracked to the front: remdesivir, made by Gilead Sciences.
The key study that led to the FDA Emergency Use Authorization in May 2020 was conducted at the Rocky Mountain Laboratories (RML) in Hamilton, Montana — by a team led by Dr. Emmie de Wit (trained at Erasmus MC Rotterdam under the same mentors as the researchers who later shaped the Proximal Origin paper). The study showed remdesivir worked in macaques. This became the primary evidence base for the EUA.
What was not disclosed in the Nature publication: RML had a "long-standing collaboration with Gilead Sciences" on remdesivir before the pandemic. This financial relationship was not declared as a conflict of interest.
Meanwhile, hydroxychloroquine (HCQ), a decades-old off-patent drug with a strong safety record, was studied as a COVID treatment. A major study in The Lancet (May 2020) claimed to show HCQ increased mortality. WHO halted its HCQ trials. Regulatory agencies issued warnings. Governments banned its use in some contexts.
The Lancet study was retracted in June 2020 — the data company it relied on, Surgisphere, could not provide the underlying dataset for verification. The damage was done. HCQ was never seriously rehabilitated in official treatment guidelines, and the narrative that it was dangerous persisted.
Two vaccines dominated the Western rollout. Both had production issues that regulators documented — and then approved around.
Pfizer used one manufacturing method for its clinical trials (a PCR-based DNA template) and a completely different method for the commercial product that went into hundreds of millions of arms (a plasmid-fermentation process, Process 2). The switch happened in October 2020, before the trials were complete.
The EMA noted in its own assessment that Pfizer's DNase enzyme step — designed to remove plasmid DNA residue — was "not demonstrated to be effective." Residual plasmid DNA was present in the commercial product in quantities that were measured differently depending on which method was used: qPCR (the regulatory standard) found one number; fluorometry (used by independent researchers) found values 36 to 153 times above the EMA/FDA limit of 10 ng per dose.
Moderna used plasmid DNA from the beginning — both in trials (Scale A, manufactured in the US) and commercially (Scale B, manufactured by Lonza in Switzerland and Rovi in Spain for EU distribution). The EMA acknowledged a critical gap: the comparability exercise between clinical trial material and commercial material for the active substance was listed as "Not applicable."
The EMA's own report stated: "no final conclusion can be drawn with regard to Scale A to Scale B comparability." The commercial product that entered EU vaccination programs had not been fully validated against the product that was tested in trials.
The EMA used something called concurrent validation — validating the manufacturing process while the vaccine was being administered to the public. The justification given: "the urgent need for this product."
The damage that the peer-reviewed literature is now documenting, study by study:
Excess mortality (Netherlands): The 65–80 age group — the most vaccinated, the most boosted — has shown +12 to +17% excess mortality for six consecutive years (2021–2026) compared to the 2019 baseline. It has not returned to baseline.
Source: CBS OData API, dataset 70895ned.
Heart damage in young men: Myocarditis after mRNA vaccine dose 2 occurs in 52 to 106 per million doses in males aged 12–24. Of those, 72% showed abnormal cardiac MRI findings — structural scarring that creates the substrate for fatal arrhythmia during exercise. The NCAA, ACC/AHA, and European Society of Cardiology all issued special return-to-play protocols, implicitly acknowledging the risk.
Source: Oster et al., JAMA 2022, PMID 35076665.
Immune suppression (IgG4-shift): After a third mRNA vaccine dose, the proportion
of spike-protein antibodies of the IgG4 subclass rises from 0.04% to 19.27% — a
480-fold increase. IgG4 antibodies cannot activate the complement system and do not trigger ADCC
(antibody-dependent cellular cytotoxicity) — the body's frontline cancer surveillance and virus-killing
mechanism. This shift is not seen after adenoviral vector vaccines. It is mRNA-specific.
Moderna's effect is stronger than Pfizer's, consistent with its 3.3x higher dose (100mcg vs 30mcg).
Sources: Irrgang et al., Science Immunology 2022, PMC9847566; Uversky et al., Vaccines 2023, PMC10222767.
Cancer rates: A South Korean registry study of 8.4 million people found elevated cancer incidence across multiple cancer types following mRNA vaccination: thyroid cancer HR 1.35, lung cancer HR 1.53, prostate cancer HR 1.69, pancreatic cancer HR 2.25 (after booster doses). The paper is currently under editorial Expression of Concern review.
Source: Ko et al., PMC12465339, 2025.
Fetal loss: An Israeli study of 226,395 pregnancies found that vaccination with dose 1 during weeks 8–13 of pregnancy was associated with +3.9 additional fetal losses per 100 pregnancies compared to expected rates. The majority of losses occurred after week 20 — consistent with progressive placental damage rather than acute immune reaction.
Source: Nazer et al., medRxiv preprint, DOI: 10.1101/2025.06.18.25329352, 2025. Note: not yet peer-reviewed.
Batch variability: Four independent peer-reviewed studies across Denmark, Sweden, Czech Republic, and Germany found that Pfizer batch lots varied by up to 10 times in serious adverse event rates. Three distinct SAE clusters were identified in Danish registry data, with statistical correlation coefficients of R²=0.68–0.89.
Sources: Schmeling et al., European Journal of Clinical Investigation 2023, DOI: 10.1111/eci.13998; Manniche et al., Medicina 2024, PMC11356762; Fürst et al., EJCI 2024, PMID 38937903; Manniche et al., Int. J. Risk & Safety in Medicine 2026.
In February 2024, the Dutch parliament launched a formal Parliamentary Inquiry into the COVID-19 measures (Parlementaire Enquête Coronamaatregelen). Public hearings began in May 2026. Among those already questioned: Dr. Marion Koopmans (who attended the February 1, 2020 narrative-shaping teleconference), OMT-chairman Jaap van Dissel, and former Prime Minister Mark Rutte.
Perhaps most significantly: the inquiry committee requested that the CTIVD — the Dutch oversight body for intelligence and security services — investigate whether those services had monitored, undermined, or targeted critics of COVID policy. The CTIVD published its report in February 2026.
The question is no longer whether the measures were excessive. Courts said so in real time. The question is whether what happened was a system failure — or a system functioning as designed.
In February 2020, Zhou et al. published the first genomic characterisation of SARS-CoV-2 in Nature, based on bronchoalveolar lavage fluid (BALF) samples collected from patients in Wuhan in December 2019 (PMID: 32015507). The raw sequencing data was deposited in public databases — NCBI SRA under accession PRJNA605983, and NGDC under PRJCA002163.
In July 2026, independent reanalysis of that raw data by Jasper Vermeer (Sovereign Health Botanicals, Belgium) and Dr. Rogier Louwen (CCassured, Netherlands) identified seven areas of concern that the original paper does not address. A formal Correction request was submitted to Nature on 11 July 2026. The original authors and Nature were notified simultaneously. The full analysis is publicly documented and reproducible.
Finding 1 — RBD-Fc fusion sequences and dual clonality: In 110 of 112 assembled genomes from the December 2019 patient cohort, the receptor binding domain (RBD) shows 100.000% nucleotide identity to NC_045512.2 over 667 nucleotides. This matches the RBD-Fc fusion construct patented by Major General Zhou Yusen of the PLA Academy of Military Medical Sciences (patent CN111333704B, filed 24 February 2020). The same clonality pattern is seen in the nsp12/RdRp region (96 of 111 assemblies at 100.000% identity over 3,212 nt). At the observed SARS-CoV-2 mutation rate, four months of natural circulation would be expected to produce approximately 1.07 substitutions per copy. The observed rate is zero in 86.5% of assemblies.
The timeline implication: the documented production time for an RBD-Fc construct is approximately four months. Counting back from the patent filing date of 24 February 2020 yields October–November 2019 — before the world knew a new virus existed.
Finding 2 — Undisclosed CRISPR/SpCas9 activity: Guide RNA scaffold sequences for the SpCas9 system are present in sample WIV05 (SRR11092061). Six targeting spacers extracted from scaffold-containing reads map exclusively to Mus musculus (mouse) genomic loci — including Cd68 (pan-macrophage marker), Procr (endothelial protein C receptor, coagulation regulation), Mecp2 (epigenetic regulator), and Sat1 (polyamine metabolism). All spacers are absent from the human genome and from the Illumina MiSeq platform control (WIV06). No CRISPR experiment is declared in the Zhou et al. methods.
Finding 3 — Sample-specific contamination with high-consequence pathogens: Avian influenza H7N9 hemagglutinin reads (KC853766) are present in all five deep-sequenced BALF samples, with a 55-fold depth difference between the highest sample (WIV07-2: 1,472× mean depth) and the next (WIV04-2: 26.65×). Nipah virus reads are present in WIV07-2 and WIV05, but yield zero reads in WIV02-2 despite that library containing 134 million reads. Neither pathogen is mentioned in the original paper. The negative control dataset (Wuhan University, Yu Zhou, CRA002390) is clean for both.
Finding 4 — GPS metadata discrepancy: 101 of the 114 assembled genomes in PRJCA002163 (NGDC, submitted January 2021) carry GPS coordinates of 38.98°N 77.11°W in the structured metadata field — the location of Walter Reed National Military Medical Center, Bethesda, Maryland, USA — while the free-text collection location reads "China: Wuhan." The first batch of samples (submitted January–March 2020) carries correct Wuhan coordinates.
Finding 5 — Phylogenetic star topology: IQ-TREE2 analysis of 117 complete assemblies shows 83 of 117 internal branches with length ≈ 0. Outgroup sequences ZC45 and ZXC21 have branch lengths 100–1,000× longer. This pattern is inconsistent with four months of natural viral evolution.
Finding 6 — Restriction enzyme signatures at spike insertions: The two SARS-CoV-2-specific spike insertions absent from RaTG13 each carry restriction enzyme recognition sequences characteristic of directional molecular cloning (NcoI at Insert 1; dual NdeI flanking the furin cleavage site at Insert 4). The two ancestrally-inherited insertions carry no equivalent signatures.
Finding 7 — Platform metadata manipulation: The five deep-sequenced BALF libraries (SRR11092059–SRR11092063) are recorded as "Illumina HiSeq 3000" in NCBI SRA. Six independent lines of evidence establish this as incorrect: FASTQ read headers contain BGI flowcell ID v300043428; depositors themselves wrote "MGISEQ-2000RS platform" in the ENA free-text field; the same authors correctly recorded MGISEQ-2000RS in the Chinese national database (NGDC). The mislabeling is selective — the co-submitted MiSeq libraries are correctly labeled on both platforms.
The timeline does not require conspiracy. It requires following the documented decisions of identifiable people, the stated contents of regulatory documents, the findings of peer-reviewed science, and the rulings of courts.
A gain-of-function research network that proposed exactly this type of enhanced virus three years before the outbreak. A pandemic declaration framework stripped of severity criteria in 2009. A PHEIC declared by a committee that was split — after its chairman visited Beijing. National emergency laws activated in advance of the international declaration. Measures mandated without evidence that has since been formally disproven by the gold standard of medical research. A vaccine approval process with documented manufacturing gaps that regulators acknowledged and approved around. And a growing body of peer-reviewed literature documenting harm that, in a functioning scientific culture, would have triggered immediate pharmacovigilance action.
The Dutch parliamentary inquiry is asking the right questions. The answers are in the documents that were always public.
This article will be updated as additional research becomes public. All cited sources are publicly available. PMIDs, DOIs, and institutional document references are provided inline. Where studies carry expressions of concern or preprint status, this is noted.